By Ben Glickman


Galapagos said it had entered an agreement with Thermo Fisher Scientific to expand manufacturing of its immune-cell cancer treatment candidate.

The company said that Thermo Fisher had agreed to provide CAR-T manufacturing and kitting services for Galapagos' CAR-T hemato-oncology clinical program in the San Francisco area.

Galapagos in November signed a deal with Landmark Bio to manufacture CAR-T in the Boston area.


Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

01-04-24 1629ET